PARP1 and neoplasm: The demonstration that tumor cells containing deleterious mutations in breast cancer (BRCA) gene 1 (BRCA1) were more sensitive to PARP inhibition than BRCA wild-type cells led to the development of PARP inhibitors, leading the FDA to approve PARP inhibitors as the first drugs designed to exploit synthetic lethality for cancer therapy (4).